CN115245523A - Application of bifidobacterium adolescentis in preparation of fat absorption inhibitor - Google Patents

Abstract

The invention relates to an application of bifidobacterium adolescentis in preparing a fat absorption inhibitor. Researches show that the bifidobacterium adolescentis can promote the expression of the gene of the angiopoietin-like protein 4 in the intestinal tract and improve the content of the angiopoietin-like protein 4 in intestinal tissues and serum, so that the activity of lipase is inhibited, fat absorption is inhibited, the influence of high-fat diet on body weight is reduced, and the development of high-safety medicaments or health-care products for preventing or treating obesity is facilitated.

Description

Application of Bifidobacterium adolescentis in the preparation of fat absorption inhibitor

technical field

The invention relates to the technical field of biomedicine, in particular to the application of Bifidobacterium adolescentis in preparing a fat absorption inhibitor.

Background technique

With economic development and changes in lifestyle, the prevalence of obesity is increasing year by year. Obesity refers to a certain degree of obvious overweight and excessive fat layer, which is a state caused by excessive accumulation of body fat, especially triglycerides. Obesity does not refer to simple weight gain, but a state of excessive accumulation of fat in the body due to excessive food intake or changes in the body's metabolism. However, obesity is a major risk factor for comorbidities such as diabetes and cardiovascular disease, and also affects the functioning of the digestive and endocrine systems. Therefore, it is necessary to control weight gain and even reduce the accumulation of body fat.

Currently, methods of weight loss include metabolic surgery, drug therapy, and lifestyle interventions. Among them, metabolic surgery is traumatic and may cause postoperative complications, and drug treatment is prone to some adverse reactions. Therefore, lifestyle intervention is the main method for weight loss at present. Lifestyle intervention is mainly through diet control and exercise to control weight gain or weight loss. Although diet control and exercise intervention can achieve good results, they are often difficult to adhere to, and diet control and exercise are highly dependent on professionalism. Diet control without professional guidance can easily lead to malnutrition, and wrong exercise methods can cause damage to joints, ligaments, etc.

SUMMARY OF THE INVENTION

Studies have found that Bifidobacterium adolescentis can promote the expression of angiopoietin-like protein 4 (Angptl4) gene in tissues, increase the content of angiopoietin-like protein 4 in intestinal tissue and serum, and inhibit the activity of lipase, thereby inhibiting fat absorption. In turn, the impact of high-fat diet on body weight is reduced, and Bifidobacterium adolescentis is a microorganism that normally exists in the healthy intestine, and can be ingested for a long time with high safety. Therefore, using Bifidobacterium adolescentis as a fat absorption inhibitor, a drug or health care product for preventing or treating obesity with high safety can be developed.

Based on this, the present invention provides an application of Bifidobacterium adolescentis in preparing a fat absorption inhibitor.

In one embodiment, the Bifidobacterium adolescentis is E298b (Variant c), and the accession number of the Bifidobacterium adolescentis is DSM 20086.

In one embodiment, the fat absorption inhibitor includes an active ingredient including the Bifidobacterium adolescentis.

In one embodiment, the fat absorption inhibitor further comprises excipients, and the excipients include a stabilizer selected from the group consisting of sodium metabisulfite, sodium bisulfite, vitamin C, cysteine, sodium ascorbate, At least one of sodium erythorbate, L-cysteine hydrochloride and edetate.

In one embodiment, the adjuvant further includes a filler selected from at least one of microcrystalline cellulose, lactose, starch, pre-interlaced starch, mannitol and sorbitol.

In one embodiment, the auxiliary material further comprises a binder, and the binder is selected from at least one selected from the group consisting of hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, povidone and crospovidone A sort of.

In one embodiment, the adjuvant further includes a disintegrant, and the disintegrant is selected from sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked carboxymethyl At least one of sodium cellulose and dry starch.

In one embodiment, the auxiliary material further includes a lubricant, and the lubricant is selected from at least one of magnesium stearate, talc, micropowder silica gel and sodium stearate fumarate.

In one embodiment, the adjuvant further includes a flavoring agent, and the flavoring agent is selected from at least one of a sweetener and an aromatic agent.

Application of Bifidobacterium adolescentis in the preparation of reagents for promoting the production of angiopoietin-like protein 4.

Description of drawings

Figure 1 shows the statistical results of the body weight of mice in the NCD group, the WD+B.a group, the WD+hk-B.a group and the WD group;

Figure 2 is the statistical result of the subcutaneous fat weight of mice in WD+B.a group, WD+hk-B.a group and WD group;

Fig. 3 is the statistical result of mesenteric white adipose tissue weight of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 4 shows the statistical results of the weight of white adipose tissue around the kidneys of mice in the WD+B.a group, the WD+hk-B.a group and the WD group;

Figure 5 is the statistical result of epididymal white adipose tissue weight of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 6 is the mRNA expression of Angptl4 gene in the ileum tissue of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 7 shows the relative quantitative results of ANGPTL4 protein expression in the ileum tissue of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 8 is the statistical result of the content of angiopoietin-like protein 4 in serum of mice in WD+B.a group, WD+hk-B.a group and WD group;

Fig. 9 is the statistical result of the activity of lipase in the ileum tissue of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 10 is the statistical result of triglyceride content in intestinal tissue of mice in WD+B.a group, WD+hk-B.a group and WD group;

Figure 11 is the statistical result of triglyceride content in dry feces of mice in WD+B.a group, WD+hk-B.a group and WD group.

Detailed ways

In order to facilitate an understanding of the present invention, the present invention will be described more fully below, which may be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terms used herein in the description of the present invention are for the purpose of describing specific embodiments only, and are not intended to limit the present invention.

Bifidobacterium is a gram-positive, immotile, rod-shaped, sometimes forked end, strictly anaerobic genus of bacteria that are widely present in the digestive tract, vagina, and oral cavity of humans and animals In other habitats, it is probiotics that maintain the health of the host. Bifidobacterium commonly used in food are: Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infants, Bifidobacterium longum and Bifidobacterium breve (Bifidobacterium breve). Among them, Bifidobacterium adolescentis can be used to treat chronic diarrhea and constipation. In addition, studies have shown that Bifidobacterium adolescentis also has a significant anti-aging effect, which can significantly increase the activity and content of superoxide dismutase (SOD) in the blood, thereby reducing the oxidation reaction of free radicals and damage to human cells, and prolonging life. effect.

According to the present invention, it is found through research that Bifidobacterium adolescentis can increase the expression of angiopoietin-like protein 4 (Angptl4) gene in the intestinal tract. Angiopoietin-like protein 4 is a lipase inhibitor, which can inhibit the expression of lipase (such as pancreatic lipase). active. Therefore, Bifidobacterium adolescentis can inhibit fat absorption by increasing the content of angiopoietin-like protein 4 and inhibiting the activity of lipase, thereby reducing the impact of high-fat diet on body weight.

Based on this, an embodiment of the present invention provides the application of Bifidobacterium adolescentis in the preparation of a reagent for promoting the production of angiopoietin-like protein 4.

Specifically, the Bifidobacterium adolescentis is E298b (Variant c), and the Bifidobacterium adolescentis was purchased from the German Collection of Microorganisms (DSMZ), and the deposit number is DSM 20086. Bifidobacterium adolescentis E298b (Variant c) is a probiotic isolated from the intestinal tract of healthy adults. It is a normal microorganism in the healthy intestinal tract. It is safe and can be ingested for a long time, and the colonization of Bifidobacterium adolescentis in the intestinal tract. strong. It has been verified that Bifidobacterium adolescentis E298b (Variant c) can increase the mRNA expression of angiopoietin-like protein 4 in ileal tissue and increase the content of angiopoietin-like protein 4 in serum.

Based on the application of the above-mentioned Bifidobacterium adolescentis in the preparation of a reagent for promoting the production of angiopoietin-like protein 4, an embodiment of the present invention also provides a reagent for promoting the production of angiopoietin-like protein 4.

Specifically, the above-mentioned agent for promoting the production of angiopoietin-like protein 4 includes Bifidobacterium adolescentis, Bifidobacterium adolescentis as the main active ingredient. Further, Bifidobacterium adolescentis is E298b (Variant c) whose deposit number is DSM 20086 of the German Collection of Microorganisms (DSMZ).

It can be understood that, in some embodiments, the above-mentioned agent for promoting angiopoietin-like protein 4 further includes an adjuvant. For example, stabilizers, fillers, binders, disintegrants, lubricants, and flavoring agents.

In some embodiments, the adjuvant is selected from at least one of stabilizers, fillers, binders, disintegrants, lubricants and flavoring agents.

Specifically, the stabilizer is used to maintain the stability of the agent that promotes angiopoietin-like protein 4, maintaining the effectiveness of its active ingredient. Specifically, the stabilizer is selected from at least one of sodium metabisulfite, sodium bisulfite, vitamin C, cysteine, sodium ascorbate, sodium erythorbate, L-cysteine hydrochloride and edetate. In one optional specific example, the stabilizer is selected from sodium metabisulfite, sodium bisulfite, vitamin C, cysteine, sodium ascorbate, sodium erythorbate, L-cysteine hydrochloride or Earthate. Of course, in other embodiments, the stabilizer is not limited to the above, and can also be other agents capable of maintaining the stability of angiopoietin-like protein 4, so that its activity is effective.

Specifically, the filler is used to increase the weight of the agent for promoting angiopoietin-like protein 4, which facilitates the forming of the agent. Optionally, the filler is selected from at least one of microcrystalline cellulose, lactose, starch, pre-interlaced starch, mannitol and sorbitol. In an alternative specific example, the filler is microcrystalline cellulose, lactose, starch, pre-interleaved starch, mannitol or sorbitol. Of course, in other embodiments, the filler is not limited to the above, and may also be other edible fillers.

Specifically, the adhesive acts as an adhesive. Optionally, the binder is selected from at least one of hydroxypropylcellulose, methylcellulose, ethylcellulose, povidone and crospovidone. In a specific example, the binder is hydroxypropylcellulose, methylcellulose, ethylcellulose, povidone or crospovidone. Of course, in other embodiments, the adhesive is not limited to the above, and can also be other edible substances with adhesive effect.

Specifically, the disintegrating agent can make the agent for promoting angiopoietin-like protein 4 be rapidly broken into fine particles in the gastrointestinal fluid, so that the active ingredient can be rapidly dissolved and absorbed. Optionally, the disintegrant is selected from at least one of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and dry starch. It can be understood that, in other embodiments, the disintegrating agent is not limited to the above, and can also be other edible substances with disintegrating effect.

Specifically, the lubricant has the functions of promoting flow, anti-sticking and lubricating, which is beneficial to the preparation of the agent for promoting angiopoietin-like protein 4. Optionally, the lubricant is selected from at least one of magnesium stearate, talc, micropowder silica gel and sodium stearate fumarate. In a specific example, the lubricant is magnesium stearate, talc, micronized silica gel or sodium stearate fumarate. It can be understood that, in other embodiments, the lubricant is not limited to the above, and can also be other edible substances with lubricating effect.

Specifically, the flavoring agent is used to improve the mouthfeel of the angiopoietin-like protein 4-promoting agent. Optionally, the flavoring agent is selected from at least one of sweeteners and flavoring agents. Optionally, the sweetener is selected from the group consisting of sorbose, xylose, xylitol, glycerin, disodium glycyrrhizinate, mannitol, mannose, galactose, maltose, lactose, fructose, sweetener, sodium saccharin, stevioside , at least one of sodium cyclamate, glucose, sucrose and aspartame; aromatics are selected from cumin oil, rose oil, rose essence, lemon oil, lemon essence, vanilla essence, vanillin, banana essence, pineapple essence, At least one of papaya flavor, peppermint oil, orange peel oil, apple flavor, orange flavor and apricot flavor. It can be understood that, in other embodiments, the flavoring agent is not limited to the above, and can also be other substances that can improve the taste.

Of course, the dosage form of the agent for promoting angiopoietin-like protein 4 is not particularly limited. Optionally, the agent for promoting angiopoietin-like protein 4 is in the form of granules, capsules or tablets.

In addition, an embodiment of the present invention also provides an application of Bifidobacterium adolescentis in preparing a fat absorption inhibitor.

In this embodiment, the Bifidobacterium adolescentis is E298b (Variant c), and the Bifidobacterium adolescentis is purchased from the German Collection of Microorganisms (DSMZ), and the deposit number is DSM 20086. Bifidobacterium adolescentis E298b (Variant c) is a probiotic in the intestinal tract of healthy adults, with high safety, long-term intake, and strong colonization in the intestinal tract. Moreover, it has been verified that Bifidobacterium adolescentis E298b (Variant c) can reduce subcutaneous fat and intra-abdominal fat at the same time, which is of great significance for improving metabolic diseases (such as obesity), and can be used as a drug for the prevention and/or adjuvant treatment of metabolic diseases , health products or food products.

Based on the application of the above-mentioned Bifidobacterium adolescentis in the preparation of a fat absorption inhibitor, an embodiment of the present invention further provides a fat absorption inhibitor. Specifically, the active ingredient of the fat absorbent includes Bifidobacterium adolescentis. Further, the active ingredient includes Bifidobacterium adolescentis E298b (Variant c) with the deposit number DSM 20086 of the German Collection of Microorganisms (DSMZ).

It can be understood that, in some embodiments, the above-mentioned fat absorption inhibitor further includes excipients. For example, the above-mentioned stabilizers, fillers, binders, disintegrants, lubricants and flavoring agents and the like. Of course, the types of excipients are not limited to the above, and can also be added according to actual conditions.

In addition, since Bifidobacterium adolescentis is a probiotic isolated from the intestinal tract of healthy adults, it is a normal microorganism in the healthy intestinal tract, which can be ingested for a long time, with high safety and strong colonization in the intestinal tract. Bifidobacterium adolescentis has been proven to reduce both subcutaneous fat and intra-abdominal fat. Therefore, an embodiment of the present invention also provides the use of Bifidobacterium adolescentis in preparing a composition for preventing or treating metabolic diseases. Specifically, the metabolic disease is obesity.

Optionally, the composition for preventing or treating metabolic diseases includes Bifidobacterium adolescentis and auxiliary materials, wherein Bifidobacterium adolescentis is used as the main active ingredient. Specifically, the adjuvant may be an adjuvant commonly used in food or medicine. In an optional specific example, the Bifidobacterium adolescentis is E298b (Variant c) with the accession number DSM 20086 of the German Collection of Microorganisms (DSMZ).

Specifically, the above-mentioned fat absorption inhibitor is used at a dose of not less than 1×10 ¹² CFU/kg·d of Bifidobacterium adolescentis. Further, the above-mentioned fat absorption inhibitor was used at a dose of 1×10 ¹² CFU/kg·d to 5×10 ¹² CFU/kg·d of Bifidobacterium adolescentis.

The above-mentioned composition for preventing or treating metabolic diseases has high safety, and can inhibit the absorption of fat by the body, so that the body is not easily obese due to the intake of high-fat food, and the above-mentioned composition for preventing or treating metabolic diseases can be used for new food or Development of medicines.

specific embodiment

The following describes in detail with reference to specific embodiments. The following examples do not include other components except inevitable impurities unless otherwise specified. Unless otherwise specified, the reagents and instruments used in the examples are routinely selected in the art. The experimental methods for which specific conditions are not indicated in the examples are realized according to conventional conditions, such as conditions described in literatures, books or methods recommended by manufacturers. The main instruments used in the following examples include animal balances, anaerobic incubators, centrifuges, Roche LightCycler 480 fluorescence quantitative PCR instrument, and ordinary optical microscopes (Olympus Corporation, Japan). Bifidobacterium adolescentis E298b (Variant c) in the following examples was purchased from the German Collection of Microorganisms (DSMZ), and the deposit number is DSM 20086. "*" in the drawings means "P<0.05", "**" means "P<0.01", "***" "P<0.001".

Example 1

(1) Bifidobacterium adolescentis E 298b (Variant c) was cultured in a medium at 37°C in an anaerobic environment for 24 hours in a shaker flask to obtain Bifidobacterium adolescentis bacterial solution; then centrifuged at 3500g for 30 minutes, and the supernatant was discarded to obtain Bifidobacterium adolescentis Bacillus precipitation; then the Bifidobacterium adolescentis precipitation was washed twice with PBS, and then resuspended in PBS containing 20% glycerol to prepare a bacterial suspension of Bifidobacterium adolescentis. Among them, the composition of the medium for culturing Bifidobacterium adolescentis E 298b (Variant c) is as follows: Casein peptone (Casein peptone) 10.00g, tryptic digest (tryptic digest) 10.00g, yeast extract (yeast extract) 5.00g g, meat extract (meat extract) 5.00g, bacto soytone (bacto soytone) 5.00g, glucose 10.00g, K ₂ HPO ₄ 2.00g, MgSO ₄ ·7H ₂ O 0.20g, MnSO ₄ ·H ₂ O 0.05g, Tween 80 1.00 mL, NaCl 5.00 g, salt solution 40.00 mL, resazurin (25 mg/100 mL) 4.00 mL, Cysteine-HCl·H ₂ O 0.50 g, and 950.00 mL distilled water. The composition of the salt solution is: CaCl ₂ ·2H ₂ O 0.25g, MgSO ₄ ·7H ₂ O 0.50g, K ₂ HPO ₄ 1.00g, KH ₂ PO ₄ 1.00g, NaHCO ₃ 10.00g, NaCl 2.00g and 1L distilled water middle. The medium is used after high temperature and high pressure sterilization.

(2) The mice were fed with ordinary chow or high-fat chow.

上海普路腾生物科技有限公司，营养成分：4.7kcal/g，含20％蛋白质，35％碳水化合物)或高脂饮食(Research diets，美国，4.73kcal/g，含20％蛋白质，35％碳水化合物，45％脂肪)开始造模。All mice of the C57BL/J6 strain (7 weeks old, male) purchased from the Institute of Model Animals of Nanjing University were housed in the SPF animal room of Shanghai Junshi Industrial Co. The rearing system uses dry sterilized corncob litter, 3 to 5 per cage, room temperature is 20 °C, relative humidity is 50%, 12 hours of light per day, day and night cycle, and free access to water and food. After a week of adaptive feeding, the mice were randomized into two groups and given a normal diet (Slycan

Shanghai Proton Biotechnology Co., Ltd., nutritional content: 4.7kcal/g, containing 20% protein, 35% carbohydrates) or high-fat diet (Research diets, USA, 4.73kcal/g, containing 20% protein, 35% carbohydrates) compound, 45% fat) to begin modeling.

(3) After 8 weeks of high-fat diet feeding, the obese mice induced by high-fat diet feeding were randomly divided into 3 groups: high-fat diet and live Bifidobacterium adolescentis treatment group (WD+B.a), high-fat diet and high fever Inactivated Bifidobacterium adolescentis treatment group (WD+hk-B.a) and high-fat diet normal drinking water group (WD). in:

Bifidobacterium adolescentis was added to the drinking water of mice in the WD+Ba group. The specific feeding of the mice in the WD+Ba group included: resuspending the Bifidobacterium adolescentis harvested in step (1) in 20% PBS glycerol to prepare The bacterial concentration was 5 × 10 ¹¹ CFU/mL bacterial suspension, and then 2 mL of bacterial suspension was diluted in 100 mL of drinking water, and the mice were allowed to eat only with water (calculated based on the daily drinking of 8 mL of water for each mouse, each mouse Daily intake of bacteria 4 × 10 ¹⁰ CFU).

The same amount of high temperature inactivated Bifidobacterium adolescentis was added to the drinking water of mice in the WD+hk-Ba group, and the mice in the WD+Ba group were fed in the same way. High temperature inactivated Bifidobacterium adolescentis was obtained by sterilizing a bacterial suspension with a bacterial concentration of 5×10 ¹¹ CFU/mL at 121° C. and 225 kPa for 15 minutes in a high temperature sterilizer.

The same amount of PBS as in the WD+B.a group was added to the drinking water of the mice in the WD group, and the mice were fed in the same way as in the WD+B.a group.

The above three different treatments were used to intervene for 5 weeks, during which the body weight was regularly weighed. The results are shown in Table 1 and Figure 1. "NCD" in Table 1 and Figure 1 refers to the normal diet group, and the water intake of the NCD group was the same as that of the WD group.

Table 1 Changes in the body weight of mice during the intervention of Bifidobacterium springa E298b (Variant c)

It can be seen from Table 1 and Figure 1 that the weight of mice in the high-fat diet group (WD group) added with PBS in the drinking water increased significantly, while the high-fat diet group (WD+ The weight gain of mice in group B.a) was not obvious, and the weight of mice in the high-fat diet group (WD+hk-B.a group) supplemented with inactivated Bifidobacterium adolescentis in drinking water also increased significantly, in which WD+hk- The average body weight of the mice in the B.a group was significantly higher than that in the WD+B.a group, and there was a significant difference between the WD+hk-B.a group and the WD+B.a group. Thus, Bifidobacterium adolescentis can slow down weight gain caused by a high-fat diet.

(4) After the 5th week, the fasting blood of the high-fat diet mice treated with the three different intervention methods in step (3) was collected through the heart, and the weight of each tissue of each group of mice was collected and weighed, After statistical analysis, the results are shown in Figures 2 to 5.

Figure 2 is the weight statistics of the subcutaneous fat of the mice in each group; Figure 3 is the weight of the mesentereic white adipose tissue (WAT) of the mice in each group; Figure 4 is the peri-renal white adipose tissue (peri-renal WAT). ) weight; Figure 5 is the weight of epididymal white adipose tissue (epididymal WAT). It can be seen from Figure 2 to Figure 5 that the weights of subcutaneous fat, mesenteric white adipose tissue, perirenal white adipose tissue and epididymal white adipose tissue of mice in WD+B.a group were significantly lower than those in WD+hk-B.a group and WD group. This shows that Bifidobacterium adolescentis can significantly reduce fat accumulation.

(5) Trizol (Invitrogen) was used to extract the total RNA of the intestinal tissues of mice in each group obtained in step (4), and reverse transcribed into cDNA using ImProm-II reverse transcriptase (Promega, USA). The relative quantitative RT-qPCR reaction was performed on the Light Cycler 480 system (Roche, USA) using Quantifast SYBR Green master mix (Qiagen, the Netherlands) to determine the mRNA expression of Angptl4 gene in the intestinal tract of mice in each group. The results are shown in Figure 6 shown.

Using ANGPTL4 antibody (Proteintech, USA) and the secondary antibody labeled with horseradish peroxidase (DAKO, Denmark) in turn, the ileal tissues of each group of mice obtained in step (4) were immunohistochemically labeled and filmed, using Image J The software performed a relative quantitative analysis of the expression of ANGPTL4 protein in the ileum tissue to obtain the area ratio of ANGPTL4 protein in the same size field, that is, the relative expression of ANGPTL4 protein. The results are shown in Figure 7.

The content of ANGPTL4 in the serum of each group of mice obtained in step (4) was determined by using the ANGPTL4 Elisa kit (Bio Vendor, Czech Republic), and the results are shown in FIG. 8 .

It can be seen from Figure 6 to Figure 8 that the expression of Angptl4 gene in the ileal tissue of mice in WD+B.a group was significantly higher than that in WD+hk-B.a group and WD group, and the content of ANGPTL4 protein in ileal tissue of mice in WD+B.a group Significantly higher than the WD+hk-B.a group and WD group, the serum ANGPTL4 content of the WD+B.a group was significantly higher than that of the WD+hk-B.a group and the WD group, indicating that Bifidobacterium adolescentis can promote the intestinal The expression of Angptl4 gene promotes the production of ANGPTL4 protein.

(6) The activity of lipoprotein lipase (LPL) in the intestinal tract of the mice in each group obtained in step (4) was measured by LPL activity assay kit (Sigma, USA), and the TG enzyme assay kit (Stanbio Labs, USA) was used. ) to measure the content of triglyceride in the intestinal tissue and intestinal cavity contents (feces) of the mice in each group. After statistical analysis, the results are shown in Figures 9 to 11, wherein:

Figure 9 shows the measurement results of lipase activity in the ileal tissue of mice in each group. It can be seen from Figure 9 that the activity of intestinal lipase (intestinal luminal lipase) of mice in the WD+B.a group was significantly lower than that in the WD group, indicating that Bifidobacterium adolescentis promoted the production of ANGPTL4 protein, thereby inhibiting the activity of lipase.

Figure 10 is the measurement result of triglyceride (TG) content in the intestinal tissue (intestine) of mice in each group; Figure 11 is the measurement result of TG content in the fecal of each group of mice. It can be seen from Figure 10 and Figure 11 that the content of triglycerides in the intestines of mice in the WD+B.a group was significantly lower than that in the WD+hk-B.a and WD groups, while the content of triglycerides in the feces of the mice in the WD+B.a group was significantly lower. Significantly higher than WD+hk-B.a group and WD group. This shows that Bifidobacterium adolescentis can significantly inhibit the intestinal absorption of fat in food, and has the effect of weight loss.

The technical features of the above-described embodiments can be combined arbitrarily. For the sake of brevity, all possible combinations of the technical features in the above-described embodiments are not described. However, as long as there is no contradiction between the combinations of these technical features, All should be regarded as the scope described in this specification.

The above-mentioned embodiments only represent several embodiments of the present invention, and the descriptions thereof are specific and detailed, but should not be construed as a limitation on the scope of the invention patent. It should be pointed out that for those of ordinary skill in the art, without departing from the concept of the present invention, several modifications and improvements can also be made, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the appended claims.

Claims (10)

1. Application of Bifidobacterium adolescentis in preparing fat absorption inhibitor is provided.

2. Use of bifidobacterium adolescentis for the preparation of a fat absorption inhibitor according to claim 1, wherein the bifidobacterium adolescentis is E298b (Variant c) and the bifidobacterium adolescentis has deposit number DSM 20086.

3. Use of bifidobacterium adolescentis for the preparation of a fat absorption inhibitor according to claim 1 or 2, wherein the fat absorption inhibitor comprises an active ingredient comprising the bifidobacterium adolescentis.

4. The use of bifidobacterium adolescentis for preparing a fat absorption inhibitor according to claim 3, further comprising an auxiliary material, wherein the auxiliary material comprises a stabilizer selected from at least one of sodium metabisulfite, sodium bisulfite, vitamin C, cysteine, sodium ascorbate, sodium erythorbate, L-cysteine hydrochloride and edetate.

5. The use of Bifidobacterium adolescentis for the preparation of a fat absorption inhibitor according to claim 4, wherein the excipient further comprises a filler selected from at least one of microcrystalline cellulose, lactose, starch, pre-crosslinked starch, mannitol and sorbitol.

6. The use of Bifidobacterium adolescentis for the preparation of a fat absorption inhibitor as claimed in claim 4, wherein the excipients further comprise a binder selected from at least one of hydroxypropylcellulose, methylcellulose, ethylcellulose, povidone and crospovidone.

7. The use of Bifidobacterium adolescentis for the preparation of a fat absorption inhibitor according to claim 4, wherein the auxiliary material further comprises a disintegrant selected from at least one of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and dry starch.

8. The use of Bifidobacterium adolescentis for the preparation of a fat absorption inhibitor according to claim 4, wherein the excipient further comprises a lubricant selected from at least one of magnesium stearate, talc, aerosil and sodium stearyl fumarate.

9. The use of Bifidobacterium adolescentis for preparing a fat absorption inhibitor according to claim 4, wherein the auxiliary material further comprises a flavoring agent selected from at least one of a sweetener and an aromatic.

10. Application of Bifidobacterium adolescentis in preparing agent for promoting production of angiopoietin-like protein 4 is provided.

Images